Program
ruxolitinib
Also written as “Ruxolitinib”, “Ruxolitinib cream” and “Ruxolitinib Cream”.
Its studies are mostly in Primary Myelofibrosis · Dermatitis, Atopic · Vitiligo · Graft vs Host Disease · Pancreatic Neoplasms, led by 3 companies.
Drug pageRuxolitinib: every studyAll 302 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Incyteits history only | 689 open or running | phase 4since Jan 13, 2023 | Jul 30, 2007 | Dec 9, 2026phase 1 · NCT07049575 |
| Novartis | 214 open or running | phase 4since Mar 16, 2012 | Jul 6, 2009 | May 10, 2029phase 4 · NCT06824103 |
| Suzhou Junjing BioSciencesits history only | 11 open or running | phase 2since Mar 27, 2025 | Mar 27, 2025 | Oct 31, 2027phase 2 · NCT06909136 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Jul 6, 2009.
- Mar 6, 2014Phase 2 study in Primary MyelofibrosisNCT02091752 · 3 enrolled · Germany, Italy, Spain
- Mar 12, 2014Phase 3 study in Primary MyelofibrosisNCT02087059 · 51 enrolled · Japan
- Sep 17, 2014Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT02253277 · 5 enrolled · Germany
- Nov 5, 2014Phase 3 study in Polycythemia VeraNCT02292446 · 161 enrolled · Austria, Belgium, Bulgaria and more
- Mar 6, 2015Phase 4 study in Primary MyelofibrosisNCT02386800 · 279 enrolled · Australia, Belgium, Bulgaria and more
- Oct 27, 2015Phase 3 study in Primary MyelofibrosisNCT02598297 · 49 enrolled · Australia, Austria, Belgium and more
- Sep 18, 2016Phase 3 study in Graft vs Host DiseaseNCT02913261 · 310 enrolled · Australia, Austria, Bulgaria and more
- Oct 18, 2016Phase 2 study in Primary MyelofibrosisNCT02966353 · 51 enrolled · Austria, Belgium, Bulgaria and more
- Mar 20, 2018Phase 2 study in Graft vs Host DiseaseNCT03491215 · 45 enrolled · Belgium, Canada, Denmark and more
- Dec 11, 2018Phase 2 study in Graft vs Host DiseaseNCT03774082 · 46 enrolled · Brazil, Canada, Czechia and more
- Apr 22, 2020Phase 3 study in Cytokine Release SyndromeNCT04362137 · 432 enrolled · United States, Argentina, Brazil and more
- Jun 5, 2024Phase 4 study in Steroid-refractory Acute Graft Versus Host DiseaseNCT06462469 · 36 enrolled · China
- Feb 4, 2025Phase 4 study in Graft vs Host DiseaseNCT06824103 · 50 planned · China
- Jan 6, 2026Phase 1 study in Primary MyelofibrosisNCT07340138 · 3 enrolled · Japan
Ahead
- May 10, 2029Primary completion: phase 4 study in Graft vs Host DiseaseNCT06824103
- Apr 5, 2032Primary completion: phase 4 study in Primary MyelofibrosisNCT02386800
TargetBeta
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
Studies
All 21 Novartis leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07340138Primary Myelofibrosis · Japan | 1 | Active, not recruiting | Jul 23, 2026 | 3 |
| NCT06824103Graft vs Host Disease · China | 4 | Recruiting | May 10, 2029 | 50 |
| NCT06462469Steroid-refractory Acute Graft Versus Host Disease · China | 4 | Active, not recruiting | Sep 3, 2026 | 36 |
| NCT04362137Cytokine Release Syndrome · United States, Argentina, Brazil and more | 3 | Completed | Oct 17, 2020 | 432 |
| NCT03774082Graft vs Host Disease · Brazil, Canada, Czechia and more | 2 | Completed | Feb 25, 2022 | 46 |
| NCT03491215Graft vs Host Disease · Belgium, Canada, Denmark and more | 2 | Completed | Mar 11, 2021 | 45 |
| NCT02966353Primary Myelofibrosis · Austria, Belgium, Bulgaria and more | 2 | Completed | Jul 24, 2018 | 51 |
| NCT02913261Graft vs Host Disease · Australia, Austria, Bulgaria and more | 3 | Completed | Jun 24, 2019 | 310 |
| NCT02598297Primary Myelofibrosis · Australia, Austria, Belgium and more | 3 | Terminated | Oct 23, 2017 | 49 |
| NCT02386800Primary Myelofibrosis · Australia, Belgium, Bulgaria and more | 4 | Active, not recruiting | Apr 5, 2032 | 279 |
| NCT02292446Polycythemia Vera · Austria, Belgium, Bulgaria and more | 3 | Completed | Dec 29, 2017 | 161 |
| NCT02253277Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany | 1 | Completed | Mar 6, 2018 | 5 |
| NCT02087059Primary Myelofibrosis · Japan | 3 | Completed | Mar 2015 | 51 |
| NCT02091752Primary Myelofibrosis · Germany, Italy, Spain | 2 | Terminated | Feb 2015 | 3 |
| NCT02049450beta-Thalassemia · Greece, Italy, Lebanon and more | 2 | Completed | Apr 12, 2016 | 30 |
| NCT02038036Polycythemia Vera · Australia, Belgium, Canada and more | 3 | Completed | Sep 29, 2015 | 149 |
| NCT01558739Primary Myelofibrosis · United Kingdom | 4 | Completed | Jan 2014 | 48 |
| NCT01493414Primary Myelofibrosis · Algeria, Argentina, Austria and more | 3 | Completed | Jan 26, 2017 | 2,233 |
| NCT01392443Primary Myelofibrosis · China, Japan, Korea, Republic of and more | 2 | Completed | Oct 31, 2017 | 120 |
| NCT01433445Primary Myelofibrosis · France, Germany, Ireland and more | 1 | Completed | Jun 22, 2020 | 61 |
| NCT00934544Primary Myelofibrosis · Austria, Belgium, France and more | 3 | Completed | Mar 4, 2015 | 219 |
How it is read
Names in the registry
- “Ruxolitinib”, 44 entries
- “Ruxolitinib cream”, 14 entries
- “Ruxolitinib Cream”, 11 entries
- “ruxolitinib”, 6 entries
- “Ruxolitinib phosphate cream”, 4 entries
Conditions, from the studies’ own filings
- Primary Myelofibrosis, 20 studies
- Dermatitis, Atopic, 13 studies
- Vitiligo, 9 studies
- Graft vs Host Disease, 8 studies
- Pancreatic Neoplasms, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.